Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (innate lymphoid cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: denileukin diftitox, inolimomab, lmb-2 +4 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 874 | 0.82 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5698
Sealed predictions
- IL2RA in dopamine neurons, braak-0.80 (p 0.010) → +0.12 (p 0.749)receipt 5705
Swarm cases
receipt 5705: IL2RA in dopamine neurons, braak
- power
- full sample -0.29 (p 0.235, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.173, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.32 (p 0.191, n 18). could be the mix.
- skeptic
- leave-one-out range -0.45 to -0.21, sign flips 0; without severely affected donors -0.29 (p 0.235, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL2RA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts